Gomekli Disease Interactions
There are 4 disease interactions with Gomekli (mirdametinib).
Mirdametinib (applies to Gomekli) cardiac disease
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Heart Disease, Cardiovascular Disease
Mirdametinib can cause left ventricular dysfunction (LVEF) and has not been studied in patients with a history of clinically significant cardiac disease or LVEF.
Mirdametinib (applies to Gomekli) liver dysfunction
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
Mirdametinib has not been studied in patients with moderate or severe liver dysfunction. No dose adjustment is recommended in patients with mild liver dysfunction.
Mirdametinib (applies to Gomekli) ocular toxicity
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Visual Defect/Disturbance
Mirdametinib can cause ocular toxicity including retinal vein occlusion (RVO), retinal pigment epithelium detachment (RPED), and blurred vision. A comprehensive ophthalmic assessment prior to initiating treatment, and at regular intervals during treatment is recommended.
Mirdametinib (applies to Gomekli) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
Mirdametinib has not been studied in patients with severe renal dysfunction. No dose adjustment is recommended in patients with mild or moderate renal dysfunction.
Switch to professional interaction data
Gomekli drug interactions
There are 11 drug interactions with Gomekli (mirdametinib).
Report options
More about Gomekli (mirdametinib)
- Gomekli consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Alecensa
Alecensa (alectinib) is an oral kinase inhibitor that may be used to treat certain types of ...
Alunbrig
Alunbrig (brigatinib) is used to treat anaplastic lymphoma kinase-positive (ALK+) metastatic ...
Koselugo
Koselugo is used to treat neurofibromatosis type 1 (NF1) in children aged 2 and older with ...
Augtyro
Augtyro (repotrectinib) is a next-generation TKI (Tyrosine Kinase Inhibitor) cancer medicine used ...
Ayvakit
Ayvakit (avapritinib) is a prescription medicine used for the treatment of gastrointestinal stromal ...
Balversa
Balversa (erdafitinib) is an oral kinase inhibitor that may be used to treat adults with locally ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Cabometyx
Cabometyx is used to treat advanced kidney cancer, liver cancer, thyroid cancer, and pancreatic and ...
Caprelsa
Caprelsa (vandetanib) is used to treat thyroid cancer that cannot be removed by surgery or that has ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
